

# Jacob P Laubach

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1228112/publications.pdf>

Version: 2024-02-01

172  
papers

9,563  
citations

57752

44  
h-index

39667

94  
g-index

173  
all docs

173  
docs citations

173  
times ranked

9414  
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. <i>British Journal of Haematology</i> , 2022, 196, 639-648.	2.5	7
2	Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma. <i>Leukemia</i> , 2022, 36, 1078-1087.	7.2	13
3	Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2022, 97, 562-573.	4.1	3
4	Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma. <i>Cancer</i> , 2022, 128, 1996-2004.	4.1	12
5	Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma. <i>Haematologica</i> , 2022, 107, 2408-2417.	3.5	19
6	Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. <i>New England Journal of Medicine</i> , 2022, 387, 132-147.	27.0	173
7	Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2022, 63, 2403-2412.	1.3	2
8	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 142-154.	10.7	46
9	Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 757-767.	1.6	98
10	Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 565-575.	1.6	98
11	Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degradors of Oncoproteins. <i>Cell Reports</i> , 2021, 34, 108532.	6.4	54
12	Phase 1 open-label study of panobinostat, lenalidomide, bortezomib+â€‰dexamethasone in relapsed and relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 20.	6.2	11
13	Improving rates of venous thromboembolism prophylaxis in multiple myeloma patients on immunomodulatory drugs through a pharmacy-based system. <i>Journal of Oncology Pharmacy Practice</i> , 2021, , 107815522199588.	0.9	2
14	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	10.7	136
15	Perceptions of prognosis in caregivers of multiple myeloma (MM) patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 12082-12082.	1.6	0
16	Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2021, 35, 3526-3533.	7.2	13
17	Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 752-765.	0.4	10
18	Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2430-2442.	1.6	53

#	ARTICLE	IF	CITATIONS
19	Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in <i>BRAF</i> -Mutated Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 6432-6444.	7.0	18
20	A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). <i>American Journal of Hematology</i> , 2021, 96, 1595-1603.	4.1	15
21	A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 149.	6.2	5
22	Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma. <i>Nature Cell Biology</i> , 2021, 23, 1199-1211.	10.3	22
23	Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma. <i>Blood</i> , 2021, 138, 4082-4082.	1.4	0
24	A Randomized Placebo-Controlled Phase 2 Study of Metformin for the Prevention of Progression of Monoclonal Gammopathy of Undetermined Significance and Low Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2021, 138, 1659-1659.	1.4	0
25	B-PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2021, 138, 4782-4782.	1.4	0
26	A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41). <i>Blood</i> , 2021, 138, 4776-4776.	1.4	1
27	Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. <i>Haematologica</i> , 2020, 105, 468-477.	3.5	41
28	A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 344-353.	7.0	66
29	Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 797-803.	0.4	5
30	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. <i>Nature Communications</i> , 2020, 11, 2996.	12.8	98
31	Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2020, 7, e370-e380.	4.6	170
32	Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib. <i>EJHaem</i> , 2020, 1, 94-102.	1.0	8
33	Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. <i>Lancet Haematology</i> , 2020, 7, e447-e455.	4.6	74
34	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy. <i>Blood</i> , 2020, 136, 45-46.	1.4	19
35	Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study. <i>Blood</i> , 2020, 136, 4-6.	1.4	3
36	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. <i>Journal of Clinical Oncology</i> , 2020, 38, 2380-2389.	1.6	110

#	ARTICLE	IF	CITATIONS
37	Clinical Outcomes of Non-Traditional Lenalidomide, Bortezomib, and Dexamethasone Regimens in Multiple Myeloma. <i>Blood</i> , 2020, 136, 25-26.	1.4	1
38	Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy: Real-World Examination of the Impede Study. <i>Blood</i> , 2020, 136, 15-16.	1.4	0
39	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 118-123.	1.3	23
40	Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 1244-1253.	4.1	42
41	Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma ( GEN 503): final results of an open-label, phase 1/2 study. <i>British Journal of Haematology</i> , 2019, 186, e35-e39.	2.5	12
42	Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older. <i>Journal of Geriatric Oncology</i> , 2019, 10, 486-489.	1.0	24
43	Evaluating the adverse effects of melphalan formulations. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1631-1637.	0.9	12
44	A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2019, 25, 478-486.	7.0	29
45	Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba. <i>Blood</i> , 2019, 134, 1906-1906.	1.4	5
46	Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update. <i>Blood</i> , 2019, 134, 691-691.	1.4	37
47	A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2019, 134, 3169-3169.	1.4	6
48	Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma. <i>Blood</i> , 2019, 134, 3178-3178.	1.4	17
49	A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: First Report of Efficacy and Safety. <i>Blood</i> , 2019, 134, 1898-1898.	1.4	6
50	Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degradors of Oncoproteins. <i>Blood</i> , 2019, 134, 318-318.	1.4	0
51	Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy. <i>Blood</i> , 2019, 134, 3091-3091.	1.4	0
52	Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. <i>British Journal of Haematology</i> , 2018, 180, 821-830.	2.5	32
53	Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 942-945.	2.4	27
54	Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. <i>Leukemia</i> , 2018, 32, 1838-1841.	7.2	42

#	ARTICLE	IF	CITATIONS
55	Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1. <i>Leukemia</i> , 2018, 32, 2032-2036.	7.2	12
56	74-Year-old female with new monoclonal protein on serum immunofixation electrophoresis. <i>Clinical Biochemistry</i> , 2018, 51, 97-100.	1.9	2
57	Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. <i>British Journal of Haematology</i> , 2018, 180, 271-275.	2.5	24
58	A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NCT00524107): final study results. <i>British Journal of Haematology</i> , 2018, 180, 41-51.	2.5	62
59	Practical Considerations for Antibodies in Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 667-674.	3.8	6
60	Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. <i>Blood Cancer Journal</i> , 2018, 8, 109.	6.2	170
61	The power of proteasome inhibition in multiple myeloma. <i>Expert Review of Proteomics</i> , 2018, 15, 1033-1052.	3.0	33
62	Ixazomib for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1949-1968.	1.8	42
63	Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. <i>British Journal of Haematology</i> , 2018, 182, 495-503.	2.5	30
64	Maintenance and continuous therapy for multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 751-764.	2.4	10
65	Geographic Disparities in Reported US Amyloidosis Mortality From 1979 to 2015. <i>JAMA Cardiology</i> , 2018, 3, 865.	6.1	71
66	A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. <i>British Journal of Haematology</i> , 2018, 182, 222-230.	2.5	118
67	Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma. <i>British Journal of Haematology</i> , 2018, 181, 433-446.	2.5	33
68	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. <i>Blood</i> , 2018, 132, 749-749.	1.4	6
69	Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2018, 132, 804-804.	1.4	42
70	Evaluation of Infusion Reactions in Patients Receiving Daratumumab Post-Implementation of an Augmented Pre- and Peri-Medication Regimen. <i>Blood</i> , 2018, 132, 3234-3234.	1.4	0
71	A Phase Ib/II Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib Plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2018, 132, 3263-3263.	1.4	1
72	Evaluation of Re-Intensification of Daratumumab to Weekly or Biweekly Dosing Schedule. <i>Blood</i> , 2018, 132, 2024-2024.	1.4	0

#	ARTICLE	IF	CITATIONS
73	A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease. Blood, 2018, 132, 1981-1981.	1.4	1
74	CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degradors of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias. Blood, 2018, 132, 1367-1367.	1.4	0
75	Improving Rates of Venous Thromboembolism Prophylaxis in Multiple Myeloma Patients on Immunomodulatory Drugs. Blood, 2018, 132, 2235-2235.	1.4	0
76	Deacetylase inhibitors: an advance in myeloma therapy?. Expert Review of Hematology, 2017, 10, 229-237.	2.2	24
77	A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. British Journal of Haematology, 2017, 178, 547-560.	2.5	48
78	Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. British Journal of Haematology, 2017, 178, 756-763.	2.5	21
79	IgM myeloma: A multicenter retrospective study of 134 patients. American Journal of Hematology, 2017, 92, 746-751.	4.1	45
80	The proteasome and proteasome inhibitors in multiple myeloma. Cancer and Metastasis Reviews, 2017, 36, 561-584.	5.9	229
81	Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma. Pharmacological Research, 2017, 117, 185-191.	7.1	25
82	Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies. JAMA Oncology, 2017, 3, 980.	7.1	77
83	Prevalence of Monoclonal Gammopathy in Wild-Type Transthyretin Amyloidosis. Mayo Clinic Proceedings, 2017, 92, 1800-1805.	3.0	55
84	Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies. Blood, 2017, 130, 902-902.	1.4	4
85	Safety of Live-attenuated Zoster Vaccination in Multiple Myeloma Patients Receiving Maintenance Lenalidomide after Autologous Stem Cell Transplantation.. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
86	Safety of MMR Vaccination in Multiple Myeloma Patients Receiving Maintenance Lenalidomide or Bortezomib after Autologous Stem Cell Transplantation.. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
87	Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood, 2016, 128, 1821-1828.	1.4	98
88	Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 2016, 374, 1621-1634.	27.0	861
89	Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood, 2016, 127, 681-695.	1.4	179
90	Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. Blood, 2016, 127, 2693-2700.	1.4	66

#	ARTICLE	IF	CITATIONS
91	Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood, 2016, 127, 2833-2840.	1.4	207
92	Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. Cancer Treatment and Research, 2016, 169, 145-167.	0.5	7
93	Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. Expert Review of Clinical Pharmacology, 2016, 9, 35-48.	3.1	24
94	Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. Blood, 2016, 128, 2122-2122.	1.4	1
95	Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone. Blood, 2016, 128, 246-246.	1.4	28
96	Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study. Blood, 2016, 128, 3326-3326.	1.4	6
97	Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. Blood, 2016, 128, 976-976.	1.4	17
98	Phase 1b study of panobinostat in combination with lenalidomide, bortezomib, and dexamethasone in relapsed refractory multiple myeloma.. Journal of Clinical Oncology, 2016, 34, 8014-8014.	1.6	7
99	IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. Blood, 2016, 128, 3276-3276.	1.4	0
100	Longer Time to Best Response and Depth of Response Are Associated with Improved Duration of Best Achieved Response and Progression-Free Survival (PFS): Post-Hoc Analysis of Phase 3 Tourmaline-MM1 Trial in Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2016, 128, 2134-2134.	1.4	0
101	A Phase II Multi-Center Study of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RsQVD) in Newly Diagnosed Multiple Myeloma - Ctrial-IE (ICORG) 13-17 Study. Blood, 2016, 128, 2117-2117.	1.4	2
102	A Pilot Study of Eltrombopag Plus G-CSF for Human CD34+ Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant. Blood, 2016, 128, 5815-5815.	1.4	0
103	Resolving the daratumumab interference with blood compatibility testing. Transfusion, 2015, 55, 1545-1554.	1.6	204
104	Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. British Journal of Haematology, 2015, 169, 851-858.	2.5	63
105	The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma. Journal of Hematology and Oncology, 2015, 8, 37.	17.0	10
106	Management of Relapsed Multiple Myeloma after Autologous Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2015, 21, 793-798.	2.0	23
107	Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clinical Cancer Research, 2015, 21, 4607-4618.	7.0	271
108	CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon. Clinical Cancer Research, 2015, 21, 2660-2662.	7.0	40



#	ARTICLE	IF	CITATIONS
109	Ibrutinib in Previously Treated Waldenström's Macroglobulinemia. New England Journal of Medicine, 2015, 372, 1430-1440.	27.0	810
110	The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. Future Oncology, 2015, 11, 1153-1168.	2.4	25
111	Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. British Journal of Haematology, 2015, 169, 843-850.	2.5	66
112	Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. New England Journal of Medicine, 2015, 373, 1207-1219.	27.0	948
113	Panobinostat for the Treatment of Multiple Myeloma. Clinical Cancer Research, 2015, 21, 4767-4773.	7.0	212
114	A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005). Blood, 2015, 126, 3036-3036.	1.4	12
115	A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. Blood, 2015, 126, 4217-4217.	1.4	8
116	Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?. Hematology American Society of Hematology Education Program, 2014, 2014, 255-261.	2.5	25
117	Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncology, The, 2014, 15, 1503-1512.	10.7	233
118	Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy. Clinical Cancer Research, 2014, 20, 3955-3961.	7.0	33
119	Current strategies for treatment of relapsed/refractory multiple myeloma. Expert Review of Hematology, 2014, 7, 97-111.	2.2	65
120	Novel Targeted Agents in the Treatment of Multiple Myeloma. Hematology/Oncology Clinics of North America, 2014, 28, 903-925.	2.2	15
121	Daratumumab granted breakthrough drug status. Expert Opinion on Investigational Drugs, 2014, 23, 445-452.	4.1	45
122	Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood, 2014, 123, 4136-4142.	1.4	125
123	Pomalidomide for the treatment of relapsed and refractory multiple myeloma. Expert Opinion on Orphan Drugs, 2014, 2, 1089-1108.	0.8	1
124	Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?. Hematology American Society of Hematology Education Program, 2014, 2014, 255-261.	2.5	16
125	An Open-Label, Dose Escalation, Multi-Center Phase 1 Study of PRLX 93936, an Agent Synthetically Active Against the Activated Ras Pathway, in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma. Blood, 2014, 124, 2140-2140.	1.4	6
126	Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenström Macroglobulinemia. Blood, 2014, 124, 3081-3081.	1.4	16



#	ARTICLE	IF	CITATIONS
127	Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma. Blood, 2014, 124, 84-84.	1.4	30
128	Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM).. Journal of Clinical Oncology, 2014, 32, 8513-8513.	1.6	19
129	MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX) Tj ETQq1 1 0.784314 rgB Clinical Oncology, 2014, 32, 8589-8589.	1.6	4
130	Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma. Blood, 2014, 124, 5777-5777.	1.4	2
131	Mimicking Myeloma Niche Ex Vivo. Blood, 2014, 124, 2076-2076.	1.4	0
132	Evaluation of Immune Profile in Patients with Multiple Myeloma Using Cytof Technology. Blood, 2014, 124, 3404-3404.	1.4	0
133	Targeting Immune Suppressive Microenvironment By Immune Checkpoint Blockade in Multiple Myeloma. Blood, 2014, 124, 27-27.	1.4	2
134	Inter and Intra-Clonal Heterogeneity in Multiple Myeloma and Waldenstrom Macroglobulinemia. Blood, 2014, 124, 2070-2070.	1.4	0
135	Clinical Translation in Multiple Myeloma: From Bench to Bedside. Seminars in Oncology, 2013, 40, 549-553.	2.2	9
136	Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood, 2013, 121, 1961-1967.	1.4	152
137	Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma. Blood, 2013, 122, 1947-1947.	1.4	4
138	MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM). Blood, 2013, 122, 1969-1969.	1.4	12
139	A Prospective Multicenter Study Of The Brutonâ€™s Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstromâ€™s Macroglobulinemia. Blood, 2013, 122, 251-251.	1.4	34
140	Molecular Analysis Of Circulating Tumor Cells Identifies Mutations That Are Distinct From Those Present In The Bone Marrow Of Patients With Multiple Myeloma. Blood, 2013, 122, 533-533.	1.4	2
141	Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma.. Journal of Clinical Oncology, 2013, 31, 8512-8512.	1.6	22
142	MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2013, 31, 8584-8584.	1.6	3
143	Phase I study of TH-302, an investigational hypoxia-targeted drug, and dexamethasone in patients with relapsed/refractory multiple myeloma.. Journal of Clinical Oncology, 2013, 31, 8602-8602.	1.6	0
144	Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Review of Hematology, 2012, 5, 51-68.	2.2	30

#	ARTICLE	IF	CITATIONS
145	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	7.2	664
146	New Proteasome Inhibitors in Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 258-266.	2.3	89
147	Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study. <i>Blood</i> , 2012, 120, 336-336.	1.4	7
148	Myeloid Derived Suppressor Cells (MDSCs) Regulate Tumor Growth, Immune Response and Regulatory T Cell (Treg) Development in the Multiple Myeloma Bone Marrow Microenvironment. <i>Blood</i> , 2012, 120, 565-565.	1.4	0
149	Formation of the Functional Niche in Vitro by Mimicking the Pathophysiological Features of the Bone Marrow Microenvironment in Multiple Myeloma. <i>Blood</i> , 2012, 120, 1812-1812.	1.4	0
150	Multiple Myeloma. <i>Annual Review of Medicine</i> , 2011, 62, 249-264.	12.2	121
151	Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. <i>Expert Review of Hematology</i> , 2011, 4, 51-60.	2.2	23
152	Management of Relapsed and Relapsed/Refractory Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 1209-1216.	4.9	22
153	Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. <i>Blood</i> , 2011, 117, 4409-4419.	1.4	141
154	Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. <i>Blood</i> , 2011, 118, 535-543.	1.4	82
155	Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 4243-4249.	1.6	118
156	Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2011, 118, 1874-1874.	1.4	1
157	Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 302-302.	1.4	28
158	Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide,. <i>Blood</i> , 2011, 118, 3966-3966.	1.4	2
159	Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial. <i>Blood</i> , 2011, 118, 480-480.	1.4	21
160	Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial. <i>Blood</i> , 2011, 118, 815-815.	1.4	0
161	RVD Induction Followed by Consolidation with ASCT in Patients with Newly Diagnosed Multiple Myeloma,. <i>Blood</i> , 2011, 118, 4134-4134.	1.4	0
162	The evolution and impact of therapy in multiple myeloma. <i>Medical Oncology</i> , 2010, 27, 1-6.	2.5	34

#	ARTICLE	IF	CITATIONS
163	Preclinical Studies of Salinomycin In Multiple Myeloma (MM) Models: Targeting of Side Population (SP) Cells In the Context of Tumor Microenvironment Interactions.. Blood, 2010, 116, 1574-1574.	1.4	28
164	Compartment-Specific Bioluminescence Imaging Platform for the Open-Ended Identification of Novel Immunomodulatory Agents and High-Throughput Evaluation of Anti-Tumor Immune Function. Blood, 2010, 116, 451-451.	1.4	0
165	Synergistic Enhancement of Conventional Anti-MM Drugs Efficacy with Plant Isothiocyanates: Therapeutic Implications. Blood, 2010, 116, 5016-5016.	1.4	0
166	Bortezomib in the management of multiple myeloma. Cancer Management and Research, 2009, Volume 1, 107-117.	1.9	8
167	Novel Therapies in the Treatment of Multiple Myeloma. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 947-960.	4.9	37
168	Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenström's Macroglobulinemia. Leukemia and Lymphoma, 2009, 50, 694-702.	1.3	31
169	Emerging Treatments for Multiple Myeloma: Beyond Immunomodulatory Drugs and Bortezomib. Seminars in Hematology, 2009, 46, 166-175.	3.4	54
170	Lack of Response to Vaccination in MGUS and Stable Myeloma.. Blood, 2009, 114, 1852-1852.	1.4	11
171	Maximizing the clinical benefit of novel therapies in multiple myeloma. Oncology, 2009, 23, 415-6, 419.	0.5	0
172	Phase I Trial of CCI-779 (Temsirrolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma. Blood, 2008, 112, 3696-3696.	1.4	26